Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

Elizabeth L. Siegler, Saad S. Kenderian

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The primary toxicities following CART cell administration are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New insights into the mechanisms of these toxicities have spurred novel treatment options. In this review, we summarize the available literature on the clinical manifestations, mechanisms, and treatments of CART-associated CRS and ICANS.

Original languageEnglish (US)
Article number1973
JournalFrontiers in immunology
Volume11
DOIs
StatePublished - Aug 28 2020

Keywords

  • CART
  • chimeric antigen receptor
  • CRS
  • immunotherapy
  • neurotoxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies'. Together they form a unique fingerprint.

Cite this